Highlights Sales of $771 million exceeded guidance range; grew 9$2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customers Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth In constant curre ...